BONESUPPORT reported orthopedic sales of SEK 219.8 million (USD $20.4 million) in 2Q24, up 56.6% from the second quarter of 2023. For the first half of the year, the company generated SEK 404.2 million (USD $37.6 million), up 55.4% from the prior period.
Increasing sales of CERAMENT G in the U.S. drove much of BONESUPPORT’s growth through the first six months of 2024. Regional sales teams focused on education and training for new users as hospital approvals continued at a high pace. Cigna decided to mirror the reimbursement level of CMS Transitional Pass-Through Payment (TPT) when using CERAMENT G in outpatient care, an important step for BONESUPPORT in establishing the product as a new standard of care.
CMS proposed extending the New Technology Add-on Payment for CERAMENT G until September 2025, with a decision expected in August 2024. Also, BONESUPPORT learned that it can follow an FDA 510(k) process for CERAMENT V instead of a DeNovo, resulting in a shorter and simpler path to clearance.
Outside the U.S., CERAMENT continued to win market share in its major markets. The company received strong results for CERAMENT G and CERAMENT V in an Australian study of 136 patients with bone infections caused by diabetes-related foot ulcers. The treatment group showed not only a significantly reduced amputation rate (2 percent, compared to 18 percent for the control group) but also shorter hospital stays. The number of days of care was 12.6 compared to 25.1 for the
control group. The results are in line with previously published European study results.
Given its strong performance so far this year, BONESUPPORT raised its 2024 guidance. The company now expects sales growth of better than 50% for the year.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment | 2Q24 | 2Q23 | $ Chg | % Chg |
---|---|---|---|---|
Orthobiologics | $20.4 | $13.1 | $7.4 | 56.6% |
Segment | 1H24 | 1H23 | $ Chg | % Chg |
---|---|---|---|---|
Orthobiologics | $37.6 | $24.2 | $13.4 | 55.4% |
Orthopedic Sales by Geography
Region | 2Q24 | 2Q23 | $ Chg | % Chg |
---|---|---|---|---|
North America | $16.1 | $9.7 | $6.4 | 66.6% |
EU and ROW | $4.3 | $3.4 | $1.0 | 28% |
Total | $20.4 | $13.1 | $7.4 | 56.6% |
Region | 1H24 | 1H23 | $ Chg | % Chg |
---|---|---|---|---|
North America | $29.2 | $17.7 | $11.6 | 65.7% |
EU and ROW | $8.3 | $6.5 | $1.8 | 27.6% |
Total | $37.6 | $24.2 | $13.4 | 55.4% |
BONESUPPORT reported orthopedic sales of SEK 219.8 million (USD $20.4 million) in 2Q24, up 56.6% from the second quarter of 2023. For the first half of the year, the company generated SEK 404.2 million (USD $37.6 million), up 55.4% from the prior period.
Increasing sales of CERAMENT G in the U.S. drove much of BONESUPPORT's growth through...
BONESUPPORT reported orthopedic sales of SEK 219.8 million (USD $20.4 million) in 2Q24, up 56.6% from the second quarter of 2023. For the first half of the year, the company generated SEK 404.2 million (USD $37.6 million), up 55.4% from the prior period.
Increasing sales of CERAMENT G in the U.S. drove much of BONESUPPORT’s growth through the first six months of 2024. Regional sales teams focused on education and training for new users as hospital approvals continued at a high pace. Cigna decided to mirror the reimbursement level of CMS Transitional Pass-Through Payment (TPT) when using CERAMENT G in outpatient care, an important step for BONESUPPORT in establishing the product as a new standard of care.
CMS proposed extending the New Technology Add-on Payment for CERAMENT G until September 2025, with a decision expected in August 2024. Also, BONESUPPORT learned that it can follow an FDA 510(k) process for CERAMENT V instead of a DeNovo, resulting in a shorter and simpler path to clearance.
Outside the U.S., CERAMENT continued to win market share in its major markets. The company received strong results for CERAMENT G and CERAMENT V in an Australian study of 136 patients with bone infections caused by diabetes-related foot ulcers. The treatment group showed not only a significantly reduced amputation rate (2 percent, compared to 18 percent for the control group) but also shorter hospital stays. The number of days of care was 12.6 compared to 25.1 for the
control group. The results are in line with previously published European study results.
Given its strong performance so far this year, BONESUPPORT raised its 2024 guidance. The company now expects sales growth of better than 50% for the year.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment | 2Q24 | 2Q23 | $ Chg | % Chg |
---|---|---|---|---|
Orthobiologics | $20.4 | $13.1 | $7.4 | 56.6% |
Segment | 1H24 | 1H23 | $ Chg | % Chg |
---|---|---|---|---|
Orthobiologics | $37.6 | $24.2 | $13.4 | 55.4% |
Orthopedic Sales by Geography
Region | 2Q24 | 2Q23 | $ Chg | % Chg |
---|---|---|---|---|
North America | $16.1 | $9.7 | $6.4 | 66.6% |
EU and ROW | $4.3 | $3.4 | $1.0 | 28% |
Total | $20.4 | $13.1 | $7.4 | 56.6% |
Region | 1H24 | 1H23 | $ Chg | % Chg |
---|---|---|---|---|
North America | $29.2 | $17.7 | $11.6 | 65.7% |
EU and ROW | $8.3 | $6.5 | $1.8 | 27.6% |
Total | $37.6 | $24.2 | $13.4 | 55.4% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.